-
If this corporate giant breaks up, shareholders should prosperFeatures The boss of pharmaceutical giant GSK has hinted the company could be split in two. That would be great news for shareholders, says Ed Bowsher.
Features -
Don’t be tempted to buy banks – here are two better optionsFeatures Bank shares might look cheap right now, but don't be tempted. There are better places to put your money, says Ed Bowsher. Here, he picks two stocks to consider instead.
Features -
Shares in focus: A health check for GlaxoFeatures There are lots of things to like about GlaxoSmithKline, but the giant pharma is also facing some big challenges, says Phil Oakley. So, should you buy the shares?
Features -
My favourite stock in the Big Pharma sectorFeatures Ed Bowsher explains what’s going on in the pharmaceuticals industry, and picks his favourite stock in the sector.
Features -
Warren Buffett’s best advice – and two stocks to go with itTutorials Ed Bowsher explains the idea behind Warren Buffett’s '20-stock punchcard' investment theory, and highlights two companies that fit the bill nicely.
Tutorials -
Buy Big Pharma – the deal spree could be just beginningFeatures With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
Features -
The best place to go hunting for value in the UK stock marketFeatures You can still find value in some UK stocks, says Ed Bowsher. Here, he explains where you should be looking, and picks three of the best stocks to buy now.
Features -
Why now looks a good time to buy this blue-chip drug giantFeatures GlaxoSmithKline has had a rotten time recently. But it’s still got plenty going for it. And now could prove a very good time to buy, says Ed Bowsher.
Features -
China's crusade against pharma giantsFeatures China has taken Western pharmaceutical companies to task over alleged corruption in the country.
Features
1
2